BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 7520348)

  • 1. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas.
    Teh M; Wee A; Raju GC
    Cancer; 1994 Sep; 74(5):1542-5. PubMed ID: 7520348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
    Lee CS; Pirdas A
    Pathology; 1995 Apr; 27(2):117-20. PubMed ID: 7567135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. nm23-H1 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
    Lee CS; Pirdas-Zivcic A
    Pathology; 1994 Oct; 26(4):448-52. PubMed ID: 7892048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of vater share a field for carcinogenesis: a population-based study.
    Henson DE; Schwartz AM; Nsouli H; Albores-Saavedra J
    Arch Pathol Lab Med; 2009 Jan; 133(1):67-71. PubMed ID: 19123739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma.
    Yokoyama Y; Hiyama E; Murakami Y; Matsuura Y; Yokoyama T
    Cancer; 1999 Nov; 86(9):1691-9. PubMed ID: 10547541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.
    Chuang SC; Lee KT; Tsai KB; Sheen PC; Nagai E; Mizumoto K; Tanaka M
    World J Surg; 2004 Oct; 28(10):995-1000. PubMed ID: 15573254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
    Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gall bladder cancer, extrahepatic bile duct cancer and ampullary carcinoma in New Zealand: Demographics, pathology and survival.
    Koea J; Phillips A; Lawes C; Rodgers M; Windsor J; McCall J
    ANZ J Surg; 2002 Dec; 72(12):857-61. PubMed ID: 12485219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival.
    Diamantis I; Karamitopoulou E; Perentes E; Zimmermann A
    Hepatology; 1995 Sep; 22(3):774-9. PubMed ID: 7657282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma.
    Lee CS
    Eur J Surg Oncol; 1997 Jun; 23(3):233-7. PubMed ID: 9236898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract.
    Sung JY; Kim GY; Lim SJ; Park YK; Kim YW
    Pathol Res Pract; 2010 Jan; 206(1):24-9. PubMed ID: 19819644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract.
    Lee CS
    Cancer; 1996 Nov; 78(9):1881-7. PubMed ID: 8909306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
    Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
    J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts.
    Argani P; Shaukat A; Kaushal M; Wilentz RE; Su GH; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Cancer; 2001 Apr; 91(7):1332-41. PubMed ID: 11283934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gallbladder and bile duct carcinoma. Biology and pathology].
    Tannapfel A; Wittekind C
    Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrahepatic biliary tract carcinoma occurring simultaneously in a married couple.
    Kennedy SM; Gillan JE; O'Beirn S; McCarthy CF; Connolly CE
    Ir J Med Sci; 1986 Jun; 155(6):204-5. PubMed ID: 3733402
    [No Abstract]   [Full Text] [Related]  

  • 17. p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction.
    Kasuya K; Nagakawa Y; Matsudo T; Ozawa T; Tsuchida A; Aoki T; Itoi T; Itokawa F
    J Hepatobiliary Pancreat Surg; 2009; 16(3):376-81. PubMed ID: 19183832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoscopic ultrasonography assessment in preoperative staging for carcinoma of ampulla of Vater and extrahepatic bile duct.
    Zhang Q; Nian W; Zhang L; Liang J
    Chin Med J (Engl); 1996 Aug; 109(8):622-5. PubMed ID: 9206064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts.
    Washington K; Gottfried MR
    Liver; 1996 Apr; 16(2):99-104. PubMed ID: 8740842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa].
    Billo P; Marchegiani C; Capella C; Sessa F
    Pathologica; 2000 Aug; 92(4):249-56. PubMed ID: 11029885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.